Mohamed Shanavas

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

Mohamed Shanavas, Uday Popat, Laura C. Michaelis et al. · Biology of Blood and Marrow Transplantation · 2015 · 142 citations · Full text

Antifibrotic Therapy, Immunology, Pathology +16

The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD

Jieun Uhm, Nada Hamad, Fotios V. Michelis et al. · Bone Marrow Transplantation · 2014 · 59 citations

Viral Persistence, Cmv Viremia, Hematology +7

Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

Mohamed Shanavas, Hans A. Messner, Eshetu G. Atenafu et al. · Bone Marrow Transplantation · 2014 · 32 citations

Hematological Malignancy, Cell Therapy, Transplantation +8

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation

Mohamed Shanavas, Hans A. Messner, Suzanne Kamel‐Reid et al. · Clinical Lymphoma Myeloma & Leukemia · 2013 · 22 citations

Transplantation, Marrow Transplantation, Medicine +12

Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Jieun Uhm, Nada Hamad, Elizabeth Shin et al. · Biology of Blood and Marrow Transplantation · 2014 · 20 citations